We are single-minded in our pursuit of a cure for Glioblastoma Multiforme (GBM) and invite you to explore our Investor Relations page to understand the financial promise that aligns with our life-changing mission.
Quarterlies
View All Financial FilingsNew Releases
View AllCNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
03 September, 2025IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
27 August, 2025Events
View AllH.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
CNS Pharmaceuticals to Participate in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Your email alerts were set.
The following alerts could not be set:
CNS Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate, TPI 287, is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggests TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.